Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Neoplasms 12Breast Neoplasms 7Triple Negative Breast Neoplasms 5Ovarian Neoplasms 4Neoplasm Metastasis 4Unspecified Adult Solid Tumor, Protocol Specific 3Sarcoma 3Lymphoma 2Carcinoma, Non-Small-Cell Lung 2Relapsed Solid Tumors 1Refractory Solid Tumors 1Prostatic Neoplasms 1Metastatic Urothelial Cell Cancer 1Melanoma 1Lung Neoplasms 1Liposarcoma 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Advanced Solid Tumors 1

Interventions

eribulin 1Irinotecan 1Cefixime 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Relapsed Solid Tumors × eribulin × Clear all
NCT02596503 2022-02-15

A Study of Eribulin in Combination With Oral Irinotecan for Adolescent and Young Adult Patients With Relapsed or Refractory Solid Tumors

University of Colorado, Denver

Phase 1 Completed
2 enrolled
Other solid neoplasm

Relapsed Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡